Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Bristol Myers Squibb Co | 150 |
| 2 | Sanofi SA | 89 |
| 3 | Merck Sharp & Dohme LLC | 57 |
| 4 | Arena Pharmaceuticals Inc | 30 |
| 5 | Pfizer Inc | 29 |
| 6 | Sanofi Aventis France | 27 |
| 7 | Genfit SA | 24 |
| 8 | Pfizer Corp SRL | 24 |
| 9 | Pfizer Products Inc | 20 |
| 10 | Abbott Healthcare Products BV | 18 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 779 |
| 2 | C07D | Heterocyclic compounds | 591 |
| 3 | A61K | Medicinal preparations | 517 |
| 4 | C07C | Acyclic and carbocyclic compounds | 106 |
| 5 | C07H | Sugars and derivatives | 102 |
| 6 | C07F | Organometallic compounds | 66 |
| 7 | C07K | Peptides | 55 |
| 8 | C07B | General methods of organic chemistry | 43 |
| 9 | G01N | Investigating / analysing materials | 43 |
| 10 | C12Q | Measuring/testing involving enzymes | 21 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Cannabis and Cannabinoid Research | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Mike Tobyn | Bristol-Myers Squibb (United Kingdom) | 5 |
| 2 | Andrew B. Dennis | Bristol-Myers Squibb (Germany) | 3 |
| 3 | Chris G. Kruse | Solvay (Netherlands) | 3 |
| 4 | Henri C. Wals | Solvay (Netherlands) | 3 |
| 5 | Herman H. van Stuivenberg | Solvay (Netherlands) | 3 |
| 6 | John F. Gamble | Bristol-Myers Squibb (United Kingdom) | 3 |
| 7 | Matthew D. Hall | National Institutes of Health | 3 |
| 8 | Amit Joharapurkar | Cadila Healthcare (India) | 2 |
| 9 | Amitgiri Goswami | Cadila Healthcare (India) | 2 |
| 10 | Andrew C. McCreary | Solvay (Netherlands) | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Surface energy analysis as a tool to probe the surface energy characteristics of micronized materials—A comparison with inverse gas chromatography | 2011 | 87 | Chemistry and Stereochemistry Studies |
| Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity‐induced chronic kidney disease | 2019 | 72 | Cannabis and Cannabinoid Research |
| Physical stability and recrystallization kinetics of amorphous ibipinabant drug product by fourier transform raman spectroscopy | 2011 | 58 | Drug Solubulity and Delivery Systems |
| Formulation and process design for a solid dosage form containing a spray-dried amorphous dispersion of ibipinabant | 2012 | 49 | Drug Solubulity and Delivery Systems |
| Roller compaction: Application of an in-gap ribbon porosity calculation for the optimization of downstream granule flow and compactability characteristics | 2010 | 39 | Drug Solubulity and Delivery Systems |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Ibipinabant?
Which organizations hold the most patents related to Ibipinabant?
What research topics are most commonly associated with Ibipinabant in the patent literature?
What are the key research areas covered in published papers on Ibipinabant?
What is the current research activity trend for Ibipinabant?